Complement C5a inhibition: a new form of COVID-19 treatment for mechanically ventilated patients?

Kalil, André C.; Proschan, Michael A.

doi:10.1016/s2213-2600(22)00365-4

Cited by 2 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29.1 g, 87%. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.56 (d,J = 7.4 Hz,1H),1H),8.03 (t,J = 7.3 Hz,2H),7.82 (t,J = 7.5 Hz,1H),7.58 (d,J = 7.8 Hz,1H),7.53 (s,1H),8H),1H),6.57 (d,J = 156.1 Hz,2H),4.65 (dt,J = 9.2,4.4 Hz,2H),4.53 (dq,J = 9.9,5.6,5.1 Hz,1H),4.43 (qd,J = 11.9,6.7 Hz,2H),4.14 (d,J = 3.4 Hz,1H),4.11 (dd,J = 11.8,7.0 Hz,1H),3.92 (dt,J = 10.2,4.8 Hz,1H),2H),2H),3.38 (dq,J = 10.4,5.7 Hz,2H), 3.07 (dtt, J = 24.2, 12.9, 5.9 Hz, 2H), 2.94 (d,J = 16.1 Hz,4H),1H),8H), 2.44 (s, 3H), 2.01 (s, 3H), 1.91 (p, J = 6.8, 6.4 Hz, 1H), 1.78 (dt, J = 12.5, 8.2 Hz, 1H), 1.62 (s, 11H), 1.45−1.36 (m, 17H), 1.27 (d,…”

Section: Preparation Of (3r6s9s15s)-15-((s)-2-((2-(tert-butoxy)-2-oxo...mentioning

confidence: 99%

“…The crude material was subjected to preparative HPLC purification using the method described below to afford the title compound, (API-1), as a white solid (14.8 g, 81%. = 11.4 Hz, 1H), 3.57 (dd,J = 11.3,4.3 Hz,1H), 3.47 (t, J = 7.2 Hz, 1H), 3.37 (dd, J = 14.9, 4.9 Hz, 1H), 3.30 (ddd, J = 13.2, 7.9, 5.0 Hz, 1H), 3.13 (dd, J = 15.0, 10.3 Hz, 1H), 3.07 (d, J = 16.5 Hz, 1H), 3.03 (t, J = 7.1 Hz, 2H), 3.00 (d,J = 16.5 Hz,1H), 2.94 (dd, J = 13.5, 6.0 Hz, 1H), 2.80 (td, J = 13.0, 11. 42, 175.05, 173.64, 173.03, 172.38, 170.21, 156.46, 136.16, 136.00, 128.87, 128.38, 126.70, 126.17, 124.11, 121.72, 119.03, 118.02, 111.68, 108.64, 69.44, 66.90, 62.20, 57.82, 55.06, 54.20, 53.45, 52.49, 50.04, 49.89, 40.29, 38.32, 38.07, 36.41, 35.90, 30.61, 30.03, 29.95, 27.66, 27.41, 26.50, 25.90, 25.72, 24.09, 23.21 Mobile phase: A acetonitrile; B water with 0.1% TFA.…”

Section: Preparation Of (3r6s9s15s)-15-((s)-2-((2-(tert-butoxy)-2-oxo...mentioning

confidence: 99%

“…The filtrates were combined and evaporated under vacuum to dryness to afford the title linear hexapeptide 17 as a white solid (33.8 g, 78%, calculated based on 28.5 mmol loading). (d,J = 17.8 Hz,1H), 3.42 (dd, J = 12.1, 5.2 Hz, 1H), 3.15 (dt, J = 14.0, 4.5 Hz, 2H), 3.06 (p, J = 6.9 Hz, 3H), 2.96 (s, 2H), 2.91 (ddd, J = 15.0, 10.7, 4.1 Hz, 1H), 2.50− 2.49 (m, 4H), 2.44 (s, 3H), 2.29−2.18 (m, 1H), 2.02 (s, 4H), 1.85 (ddt, J = 13.5, 9.2, 4.9 Hz, 1H), 1.75 (q, J = 7.6, 7.0 Hz, 1H), 1.63 (s, 10H), 1.61−1.44 (m, 3H), 1.45−1.34 (m, 17H), 1.29 (s, 4H), 1.26 (s, 6H), 1.14 (s, 14H), 0.93 (s, 2H). Doubled resonances consistent with a rotamer observed.…”

Section: Preparation Of Resin-bound (S)-5-amino-2-((s)-2-((2-(tertbut...mentioning

confidence: 99%

See 2 more Smart Citations

Improved Synthesis of a Macrocyclic Peptide-Like C5aR Antagonist for Intravenous Applications

Feng,

Liang,

Langille

et al. 2023

Org. Process Res. Dev.

View full text Add to dashboard Cite

A multigram scale synthetic procedure for the preparation of a complex and polar macrocyclic peptidic C5aR antagonist is described. The route was developed through improvements to an initial small-scale research synthesis and hinged on optimized solid-phase peptide synthesis featuring an early side chain decoration, a highly efficient off-resin macrolactamization, and global deprotection steps. These improvements resulted in a reduction in off-resin peptide manipulations and ultimately to a 6-fold increase in overall yield from 2-chlorotrityl-bound intermediate SP-7c.

show abstract

Section: Preparation Of (3r6s9s15s)-15-((s)-2-((2-(tert-butoxy)-2-oxo...mentioning

confidence: 99%

Section: Preparation Of (3r6s9s15s)-15-((s)-2-((2-(tert-butoxy)-2-oxo...mentioning

confidence: 99%

Section: Preparation Of Resin-bound (S)-5-amino-2-((s)-2-((2-(tertbut...mentioning

confidence: 99%

See 1 more Smart Citation

Improved Synthesis of a Macrocyclic Peptide-Like C5aR Antagonist for Intravenous Applications

Feng,

Liang,

Langille

et al. 2023

Org. Process Res. Dev.

View full text Add to dashboard Cite

show abstract

Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis

et al. 2022

View full text Add to dashboard Cite

BackgroundSince the global epidemic of the coronavirus disease 2019 (COVID-19), a large number of immunological studies related to COVID-19 have been published in various immunology journals. However, the results from these studies were discrete, and no study summarized the important immunological information about COVID-19 released by these immunology journals. This study aimed to comprehensively summarize the knowledge structure and research hotspots of COVID-19 published in major immunology journals through bibliometrics.MethodsPublications on COVID-19 in major immunology journals were obtained from the Web of Science Core Collection. CiteSpace, VOSviewer, and R-bibliometrix were comprehensively used for bibliometric and visual analysis.Results1,331 and 5,000 publications of 10 journals with high impact factors and 10 journals with the most papers were included, respectively. The USA, China, England, and Italy made the most significant contributions to these papers. University College London, National Institute of Allergy and Infectious Diseases, Harvard Medical School, University California San Diego, and University of Pennsylvania played a central role in international cooperation in the immunology research field of COVID-19. Yuen Kwok Yung was the most important author in terms of the number of publications and citations, and the H-index. CLINICAL INFECTIOUS DISEASES and FRONTIERS IN IMMUNOLOGY were the most essential immunology journals. These immunology journals mostly focused on the following topics: “Delta/Omicron variants”, “cytokine storm”, “neutralization/neutralizing antibody”, “T cell”, “BNT162b2”, “mRNA vaccine”, “vaccine effectiveness/safety”, and “long COVID”.ConclusionThis study systematically uncovered a holistic picture of the current research on COVID-19 published in major immunology journals from the perspective of bibliometrics, which will provide a reference for future research in this field.

show abstract

Complement C5a inhibition: a new form of COVID-19 treatment for mechanically ventilated patients?

Cited by 2 publications

References 16 publications

Improved Synthesis of a Macrocyclic Peptide-Like C5aR Antagonist for Intravenous Applications

Improved Synthesis of a Macrocyclic Peptide-Like C5aR Antagonist for Intravenous Applications

Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis

Contact Info

Product

Resources

About